Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.

Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.

Hypertension,Essential

Obesity

Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning

acetylsalicylic acid

Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning

Tomato Fruit Extract

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk

The platelet inhibition after STE and ASA therapy (VerifyNow Aspirin for ASA and STE Groups and VerifyNow P2Y12 for STE Group only) The platelet reactivity measurements will be performed using the VerifyNow Tests (Accumetrics Inc., USA) method.

The reduction in office BP (measured three times in standard conditions) and in 24-hour ABPM parameters

Beata Krasinska

Principal Investigator

This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity

Myeloproliferative Neoplasms

SGI-110

Weill Cornell Medical College

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Complete remission rate is defined as number of subjects with complete remission according to the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Hematological response is defined as number of subjects with hematological response according to the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Spleen response rate is defined as improvement in size of spleen as measured by US/CT scan and according to the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Symptom improvement response is defined as number of subjects with improvement in symptoms response as defined by Myelofibrosis Symptom Assessment Form (MF-SAF)

cytidine/hemorrhage

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Baz done ki pi konplè remèd fèy medsin te apiye nan syans